Today, with the combined expertise of CSL Behring (with oversight to CSL Plasma), CSL Seqirus, and CSL Vifor—and our singular commitment to relentlessly innovate—CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they deserve. We’re always improving so life can, too.
CSL Plasma operates one of the world’s largest and most sophisticated plasma collection networks, with nearly 330 plasma donation centers globally, including the U.S. and Europe and employs nearly 16,000 employees. CSL Plasma is vertically integrated, meaning plasma collected at CSL Plasma facilities is used by CSL Behring for the sole purpose of manufacturing and delivering its life-saving ...
CSL CSL is a global biopharma company working to create enduring impact for patients and public health. OUR GLOBAL MANUFACTURING AND OFFICE PRESENCE OUR BUSINESS US$15.6b in annual revenue 100+ countries that CSL provides lifesaving products to patients US$2.92 dividend per share for 2025 CSL uses its deep expertise in plasma-derived therapies, vaccines and biotechnology to deliver medicines ...
CSL consists of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor. Learn more by visiting each section.
CSL will outlay $1.5bn over the next five years in the US to grow its footprint of plasma therapy production, the latest pharma company to pour money into the country amid tariff threats.
FiercePharma: CSL telegraphs 300 new hires as it breaks ground on $1.5B plasma-based medicine plant near Chicago
After teasing a plasma-based manufacturing expansion in the U.S. late last year, CSL is putting in the work and firming up details behind the $1.5 billion project. Monday, the Australian biopharma ...